COMMUNIQUÉS West-GlobeNewswire

HepatoBurn 2025: Experts Discuss the Mitochondrial Science Behind Hepato Burn Emerging Weight Support Formula
23/06/2025
HepatoBurn gains momentum in metabolic circles for its mitochondria-driven formula designed to aid liver fat processing and support weight balance. New York City, NY, June 23, 2025 (GLOBE NEWSWIRE) -- In 2025, the [...]
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
23/06/2025
Pending a decision from the European Commission, Ozempic ® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, demonstrating improvements in [...]
Bioma Probiotics Officially Launches: A Revolutionary Step Toward Total Gut Health
23/06/2025
Bioma Probiotics combines prebiotics, probiotics & postbiotics to support digestion, reduce bloating, and boost mood naturally. new york City, NY, June 23, 2025 (GLOBE NEWSWIRE) -- Bioma Probiotics In a bold move to [...]
SickKids staff to join hospital workers across Ontario as members of the Healthcare of Ontario Pension Plan (HOOPP)
23/06/2025
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan (HOOPP) and The Hospital for Sick Children (SickKids) are pleased to announce that SickKids employees will become members of HOOPP’s [...]
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
23/06/2025
Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate that Sana’s [...]
Simple Divorce Releases New Study on Impact of Economic Factors on Divorce Rates in Ontario
23/06/2025
Toronto, Ontario, June 23, 2025 (GLOBE NEWSWIRE) -- A recent study from Simple Divorce has uncovered a compelling connection between financial stress and increasing divorce rates across Ontario. The findings shine a [...]
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
23/06/2025
Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
23/06/2025
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Data from the Phase 2 Clinical Trial of CX11/VCT220 in China Presented at ADA 2025
23/06/2025
Patients treated with CX11 (also designated as VCT220) achieved a 9.7% and 9.4% decrease in body weight from baseline after 16 weeks (p≤0.001) in the 160 mg fast and slow titration cohorts, respectively. Results suggest [...]
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
23/06/2025
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia [...]
Optime Care Partners with Tilde Sciences as Exclusive Specialty Pharmacy Provider for Vecamyl
23/06/2025
ST. LOUIS, June 23, 2025 (GLOBE NEWSWIRE) -- Optime Care , AscellaHealth’s Specialty Pharmacy, is pleased to announce an expanded partnership with Tilde Sciences LLC (“Tilde”), effective June 23, 2025. Under this [...]
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
23/06/2025
RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal [...]
Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases
23/06/2025
PARMA, Italy, June 23, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today [...]
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
23/06/2025
Dr. Moraitis brings deep experience in endocrinology to his role leading clinical development for MBX’s lead product candidate, canvuparatide CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq [...]
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
23/06/2025
Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First [...]
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
23/06/2025
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase [...]
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
23/06/2025
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial reduction in T cell [...]
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients
23/06/2025
PORTICO-2 designed to validate vafidemstat’s efficacy in reducing aggression in BPD patients Primary endpoint: STAXI-2 Trait Anger (patient-reported) Key secondary endpoint: Overt Aggression Scale-Modified (OAS-M) ( [...]
Kestra Medical Technologies Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
23/06/2025
KIRKLAND, Wash., June 23, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that the company will be added to the [...]

Pages